American Journal of Nephrology

Patient-Oriented, Translational Research: Research Article

Vrist M.H.a,b· Østergaard A.M.H.a,b· Langaa S.S.a,b· Mose F.H.a,b· Fynbo C.A.c· Theil J.b,c· Langdahl B.L.d· Lauridsen T.G.e· Bech J.N.a,b

Author affiliations

aUniversity Clinic in Nephrology and Hypertension, Gødstrup Hospital, Herning, Denmark
bUniversity Clinic in Nephrology and Hypertension, Aarhus University, Aarhus, Denmark
cDepartment of Nuclear Medicine, Gødstrup Hospital, Herning, Denmark
dDepartment of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
eDepartment of Nephology, Aalborg University Hospital, Aalborg, Denmark

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud Rent for 48h to view Buy Cloud Access for unlimited viewing via different devices Synchronizing in the ReadCube Cloud Printing and saving restrictions apply Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: February 17, 2022
Accepted: April 18, 2022
Published online: June 07, 2022

Number of Print Pages: 13
Number of Figures: 5
Number of Tables: 5

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: https://www.karger.com/AJN

Abstract

Introduction: Invasive bone biopsy to assess bone metabolism in patients with chronic kidney disease-mineral and bone disorder may be replaced by the noninvasive 18F-NaF PET/CT and biomarkers of bone metabolism. We aimed to compare parameters of bone turnover, mineralization, and volume assessed by bone biopsies with results derived from 18F-NaF PET/CT and biomarkers (bone-specific alkaline phosphatase, osteocalcin, fibroblast growth factor 23, and osteoprotegerin). Methods: A cross-sectional study included 17 dialysis patients, and results from 18F-NaF PET/CT scans and the biomarkers were directly compared with the results of histomorphometric analyses of tetracycline double-labeled trans-iliac bone biopsies. Results: Bone biopsies showed 40% high, 20% normal, and 40% low bone turnover. No biopsies had generalized abnormal mineralization, and the bone volume/total tissue volume was low in 80% and high in 7%. The pelvic skeletal plasma clearance (Ki) from 18F-NaF PET/CT correlated with bone turnover parameters obtained by bone biopsy (activation frequency: r = 0.82, p < 0.01; bone formation rate/bone surface: r = 0.81, p < 0.01), and Ki defined low turnover with high sensitivity (83%) and specificity (100%). CT-derived radiodensity correlated with bone volume, r = 0.82, p < 0.01. Of the biomarkers, only osteocalcin showed a correlation with turnover assessed by histomorphometry. Conclusion: In conclusion, 18F-NaF PET/CT may be applicable for noninvasive assessment of bone turnover and volume in CKD-MBD.

© 2022 S. Karger AG, Basel

References Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, Cadarette SM, et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014;86(4):810–8. Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA. 2002;288(23):3014–8. Liu SH, Chu HI. Treatment of renal osteodystrophy with dihydrotachysterol (A.T.10) and iron. Science. 1942;95(2467):388–9. Lucas RC. On a form of late rickets associated with albuminuria, rickets of adolecents. Lancet. 1883;1:993–4. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).Kidney Int Suppl. 2017;7(1):1–59. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53. Messa C, Goodman WG, Hoh CK, Choi Y, Nissenson AR, Salusky IB, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab. 1993;77(4):949–55. Aaltonen L, Koivuviita N, Seppänen M, Tong X, Kröger H, Löyttyniemi E, et al. Correlation between (18)F-sodium fluoride positron emission tomography and bone histomorphometry in dialysis patients. Bone. 2020;134:115267. Schreiber JJ, Anderson PA, Rosas HG, Buchholz AL, Au AG. Hounsfield units for assessing bone mineral density and strength: a tool for osteoporosis management. J Bone Joint Surg Am. 2011;93(11):1057–63. Baptista AL, Padilha K, Malagrino PA, Venturini G, Zeri AC, Dos Reis LM, et al. Potential biomarkers of the turnover, mineralization, and volume classification: results using NMR metabolomics in hemodialysis patients. JBMR Plus. 2020;4(7):e10372. Couttenye MM, D’Haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant. 1996;11(6):1065–72. Delanaye P, Souberbielle JC, Lafage-Proust MH, Jean G, Cavalier E. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts. Nephrol Dial Transplant. 2014;29(5):997–1004. Lima F, El-Husseini A, Monier-Faugere MC, David V, Mawad H, Quarles D, et al. FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis. Clin Nephrol. 2014;82(5):287–95. Gonnelli S, Montagnani A, Caffarelli C, Cadirni A, Campagna MS, Franci MB, et al. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. J Endocrinol Invest. 2005;28(6):534–9. Bordier P, Matrajt H, Miravet L, Hioco D. Histological measure of the volume and resorption of bone joints. Pathol Biol. 1964;12:1238–43. Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res. 1969;3(3):211–37. Melsen F, Melsen B, Mosekilde L, Bergmann S. Histomorphometric analysis of normal bone from the iliac crest. Acta Pathol Microbiol Scand A. 1978;86(1):70–81. Steiniche T, Eriksen EF, Kudsk H, Mosekilde L, Melsen F. Reconstruction of the formative site in trabecular bone by a new, quick, and easy method. Bone. 1992;13(2):147–52. Steiniche T, Christiansen P, Vesterby A, Hasling C, Ullerup R, Mosekilde L, et al. Marked changes in iliac crest bone structure in postmenopausal osteoporotic patients without any signs of disturbed bone remodeling or balance. Bone. 1994;15(1):73–9. Malluche HH, Monier-Faugere MC. Renal osteodystrophy: what’s in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol. 2006;65(4):235–42. Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011;26(6):1368–76. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28(1):2–17. Vrist MH, Bech JN, Lauridsen TG, Fynbo CA, Theil J. Comparison of [18F] NaF PET/CT analysis methods and derivation of a semi-population input function for site specific measurements of bone formation in a population with chronic kidney disease mineral and bone disorder. EJNMMI Res. 2021;11(1):117. Siddique M, Blake GM, Frost ML, Moore AE, Puri T, Marsden PK, et al. Estimation of regional bone metabolism from whole-body 18F-fluoride PET static images. Eur J Nucl Med Mol Imaging. 2012;39(2):337–43. Vrist MH, Bech JN, Lauridsen TG, Fynbo CA, Theil J. Comparison of [18F] NaF PET/CT dynamic analysis methods and a static analysis method including derivation of a semi-population input function for site-specific measurements of bone formation in a population with chronic kidney disease mineral and bone disorder. EJNMMI Res. 2021;11(1):117. Frost ML, Siddique M, Blake GM, Moore AE, Schleyer PJ, Dunn JT, et al. Differential effects of teriparatide on regional bone formation using (18)F-fluoride positron emission tomography. J Bone Miner Res. 2011;26(5):1002–11. Blake GM, Siddique M, Puri T, Frost ML, Moore AE, Cook GJ, et al. A semipopulation input function for quantifying static and dynamic 18F-fluoride PET scans. Nucl Med Commun. 2012;33(8):881–8. Al-Beyatti Y, Siddique M, Frost ML, Fogelman I, Blake GM. Precision of (1)(8)F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism. Osteoporos Int. 2012;23(10):2535–41. Heaf J. Danish nephology registry. Annu Rep. 2017. Zamboch K, Krejčí K, Škarda J, Tichý M, Überall I, Skýpalová P, et al. Histomorphometric diagnostics of renal osteopathy in chronic dialysis patients at high risk of cardiovascular disease. Int Urol Nephrol. 2015;47(7):1195–201. Liangos O, Kirchhoff S, Buchholz J, Ketteler M. Bone biopsy results in chronic kidney disease: a single-center experience. Kidney Blood Press Res. 2018;43(4):1222–30. Carbonara CEM, Reis LMD, Quadros KRDS, Roza NAV, Sano R, Carvalho AB, et al. Renal osteodystrophy and clinical outcomes: data from the Brazilian Registry of Bone Biopsies – REBRABO. J Bras Nefrol. 2020;42(2):138–46. Amerling R, Harbord NB, Pullman J, Feinfeld DA. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif. 2010;29(3):293–9. Charles P, Poser JW, Mosekilde L, Jensen FT. Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion. J Clin Invest. 1985 Dec;76(6):2254–8. Hiller RG, Patecki M, Neunaber C, Reifenrath J, Kielstein JT, Kielstein H. A comparative study of bone biopsies from the iliac crest, the tibial bone, and the lumbar spine. BMC Nephrol. 2017;18(1):134. Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016;67(4):559–66. Gardham C, Stevens PE, Delaney MP, LeRoux M, Coleman A, Lamb EJ. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol. 2010;5(7):1261–7. Hocher B, Armbruster FP, Stoeva S, Reichetzeder C, Grön HJ, Lieker I, et al. Measuring parathyroid hormone (PTH) in patients with oxidative stress – do we need a fourth generation parathyroid hormone assay? PLoS One. 2012;7(7):e40242. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70(2):345–50. Keronen S, Martola L, Finne P, Burton IS, Kauppila L, Kröger H, et al. Bone histomorphometry and indicators of bone and mineral metabolism in wait-listed dialysis patients. Clin Nephrol. 2016;85(3):127–34. Carvalho AB, Carneiro R, Leme GM, Rochitte CE, Santos RD, Miname MH, et al. Vertebral bone density by quantitative computed tomography mirrors bone structure histomorphometric parameters in hemodialysis patients. J Bone Miner Metab. 2013 Sep;31(5):551–5. Blomquist GA, Davenport DL, Mawad HW, Monier-Faugere MC, Malluche HH. Diagnosis of low bone mass in CKD-5D patients. Clin Nephrol. 2016;85(2):77–83. Dworak TC, Wagner SC, Nappo KE, Balazs GC, Grimm PD, Colantonio DF, et al. The use of distal Ulnar Hounsfield units to predict future fragility fracture risk. J Hand Surg Am. 2018;43(11):1010–5. Article / Publication Details

First-Page Preview

Received: February 17, 2022
Accepted: April 18, 2022
Published online: June 07, 2022

Number of Print Pages: 13
Number of Figures: 5
Number of Tables: 5

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: https://www.karger.com/AJN

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.